Foghorn Therapeutics Inc. Cash Flow Statement
FHTX|6 years of annual SEC 10-K data (FY2020-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 6 fiscal years. All figures from audited SEC 10-K filings.
Foghorn Therapeutics Inc. used $100M in operating cash flow and negative free cash flow of $101M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -1.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income | -$86.6M | -$98.4M | -$108.9M | -$101.3M | -$68.8M | -$51.1M |
| Depreciation & Amortization | $3.1M | $3.5M | $3.3M | $3.2M | $1.3M | $693.0K |
| Operating Cash Flow | -$100.4M | -$118.1M | $193.6M | -$50.3M | -$31.3M | -$46.3M |
| Capital Expenditures | $906.0K | $1.2M | $1.2M | $3.3M | $16.2M | $968.0K |
| Free Cash Flow | -$101.3M | -$119.3M | $192.4M | -$53.6M | -$47.5M | -$47.3M |
| FCF Margin | -448.2% | -349.4% | 1000.6% | -4060.9% | -11039.3% | -11000.7% |